Urology, ISSN 0090-4295, 2015, Volume 85, Issue 4, pp. 717 - 724
Radium-223 dichloride (radium-223) is an important therapeutic option for the treatment of patients with castration-resistant prostate cancer, symptomatic bone...
Urology | SURVIVAL | MULTICENTER | RA-223 | BONE METASTASES | SKELETAL-RELATED EVENTS | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | RANDOMIZED-TRIAL | PHASE-II | ENZALUTAMIDE | ABIRATERONE | Attitude of Health Personnel | Radioisotopes - therapeutic use | Humans | Radioisotopes - adverse effects | Bone Neoplasms - secondary | Male | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Radium - adverse effects | Prostatic Neoplasms, Castration-Resistant - drug therapy | Radium - therapeutic use | Prostatic Neoplasms, Castration-Resistant - pathology | Patient Selection | Antineoplastic Agents - adverse effects | Bone Neoplasms - drug therapy | Patient Education as Topic | Practice Guidelines as Topic | Prevention | Metastasis | Prostate cancer | Cancer
Urology | SURVIVAL | MULTICENTER | RA-223 | BONE METASTASES | SKELETAL-RELATED EVENTS | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | RANDOMIZED-TRIAL | PHASE-II | ENZALUTAMIDE | ABIRATERONE | Attitude of Health Personnel | Radioisotopes - therapeutic use | Humans | Radioisotopes - adverse effects | Bone Neoplasms - secondary | Male | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Radium - adverse effects | Prostatic Neoplasms, Castration-Resistant - drug therapy | Radium - therapeutic use | Prostatic Neoplasms, Castration-Resistant - pathology | Patient Selection | Antineoplastic Agents - adverse effects | Bone Neoplasms - drug therapy | Patient Education as Topic | Practice Guidelines as Topic | Prevention | Metastasis | Prostate cancer | Cancer
Journal Article
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 06/2017, Volume 18, Issue 9, pp. 945 - 952
Introduction: Androgen deprivation therapy (ADT) is a mainstay initial treatment for advanced hormone-sensitive prostate cancer (HSPC), but disease progression...
prostate cancer | Androgen receptor antagonist | ARAFOR | darolutamide | ODM-201 | ARADES | DIAGNOSIS | SAFETY | GUIDELINES | MECHANISMS | PHASE-2 | RESISTANCE | PHARMACOLOGY & PHARMACY | INCREASED SURVIVAL | ANDROGEN RECEPTOR INHIBITOR | ENZALUTAMIDE | ABIRATERONE | Pyrazoles - therapeutic use | Androgen Receptor Antagonists - therapeutic use | Administration, Oral | Humans | Receptors, Androgen - metabolism | Androgen Receptor Antagonists - administration & dosage | Male | Prostatic Neoplasms, Castration-Resistant - drug therapy | Androgen Receptor Antagonists - adverse effects | Disease Progression | Disease-Free Survival | Clinical Trials, Phase III as Topic | Pyrazoles - administration & dosage | Pyrazoles - adverse effects
prostate cancer | Androgen receptor antagonist | ARAFOR | darolutamide | ODM-201 | ARADES | DIAGNOSIS | SAFETY | GUIDELINES | MECHANISMS | PHASE-2 | RESISTANCE | PHARMACOLOGY & PHARMACY | INCREASED SURVIVAL | ANDROGEN RECEPTOR INHIBITOR | ENZALUTAMIDE | ABIRATERONE | Pyrazoles - therapeutic use | Androgen Receptor Antagonists - therapeutic use | Administration, Oral | Humans | Receptors, Androgen - metabolism | Androgen Receptor Antagonists - administration & dosage | Male | Prostatic Neoplasms, Castration-Resistant - drug therapy | Androgen Receptor Antagonists - adverse effects | Disease Progression | Disease-Free Survival | Clinical Trials, Phase III as Topic | Pyrazoles - administration & dosage | Pyrazoles - adverse effects
Journal Article
Annals of Oncology, ISSN 0923-7534, 2015, Volume 26, Issue 8, pp. 1589 - 1604
The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most...
Castration-resistant prostate cancer | Advanced prostate cancer | Castration-naïve prostate cancer | Consensus | Therapeutics | therapeutics | INTERMITTENT ANDROGEN SUPPRESSION | BONE METASTASES | castration-naive prostate cancer | PHASE-III | OPEN-LABEL | castration-resistant prostate cancer | ANTITUMOR-ACTIVITY | advanced prostate cancer | consensus | ZOLEDRONIC ACID | ONCOLOGY | ABIRATERONE ACETATE | METASTASIS-FREE SURVIVAL | SPINAL-CORD COMPRESSION | III EXTENSION TRIAL | Prostatic Neoplasms - pathology | Adenocarcinoma - pathology | Humans | Bone Density Conservation Agents - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Prostatic Neoplasms, Castration-Resistant - pathology | Orchiectomy | Prostatic Neoplasms - therapy | Taxoids - therapeutic use | Adenocarcinoma - therapy | Antineoplastic Agents, Hormonal - therapeutic use | Androgen Antagonists - therapeutic use | Prostatic Neoplasms, Castration-Resistant - therapy | Prostatectomy | Radiotherapy, Adjuvant | Practice Guidelines as Topic | Special | castration-naïve prostate cancer
Castration-resistant prostate cancer | Advanced prostate cancer | Castration-naïve prostate cancer | Consensus | Therapeutics | therapeutics | INTERMITTENT ANDROGEN SUPPRESSION | BONE METASTASES | castration-naive prostate cancer | PHASE-III | OPEN-LABEL | castration-resistant prostate cancer | ANTITUMOR-ACTIVITY | advanced prostate cancer | consensus | ZOLEDRONIC ACID | ONCOLOGY | ABIRATERONE ACETATE | METASTASIS-FREE SURVIVAL | SPINAL-CORD COMPRESSION | III EXTENSION TRIAL | Prostatic Neoplasms - pathology | Adenocarcinoma - pathology | Humans | Bone Density Conservation Agents - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Prostatic Neoplasms, Castration-Resistant - pathology | Orchiectomy | Prostatic Neoplasms - therapy | Taxoids - therapeutic use | Adenocarcinoma - therapy | Antineoplastic Agents, Hormonal - therapeutic use | Androgen Antagonists - therapeutic use | Prostatic Neoplasms, Castration-Resistant - therapy | Prostatectomy | Radiotherapy, Adjuvant | Practice Guidelines as Topic | Special | castration-naïve prostate cancer
Journal Article
UROLOGY, ISSN 0090-4295, 05/2011, Volume 77, Issue 5, pp. 1095 - 1095
Journal Article
BJU International, ISSN 1464-4096, 09/2015, Volume 116, Issue 3, pp. 321 - 329
The principal role of the immune system is to prevent and eradicate pathogens and infections. The key characteristics or features of an effective immune...
cytokine | immunotherapy | cancer | monoclonal antibody | immunoediting | checkpoint inhibitor | therapeutic cancer vaccine | SURVIVAL | IMMUNITY | NATURAL-KILLER | VIRUS | MONOCLONAL-ANTIBODY | PROSTATE-CANCER | UROLOGY & NEPHROLOGY | AGENTS | BLOCKADE | T-CELLS | VACCINES | Cytokines | Neoplasms - immunology | Cancer Vaccines | Humans | Immunotherapy | Antibodies, Monoclonal - therapeutic use | Neoplasms - drug therapy | Monoclonal antibodies | Development and progression | Care and treatment | Drug therapy | Cancer | Immune system
cytokine | immunotherapy | cancer | monoclonal antibody | immunoediting | checkpoint inhibitor | therapeutic cancer vaccine | SURVIVAL | IMMUNITY | NATURAL-KILLER | VIRUS | MONOCLONAL-ANTIBODY | PROSTATE-CANCER | UROLOGY & NEPHROLOGY | AGENTS | BLOCKADE | T-CELLS | VACCINES | Cytokines | Neoplasms - immunology | Cancer Vaccines | Humans | Immunotherapy | Antibodies, Monoclonal - therapeutic use | Neoplasms - drug therapy | Monoclonal antibodies | Development and progression | Care and treatment | Drug therapy | Cancer | Immune system
Journal Article
Canadian Urological Association Journal, ISSN 1920-1214, 12/2018, Volume 12, Issue 12, pp. 377 - 377
Journal Article
UROLOGY, ISSN 0090-4295, 11/2010, Volume 76, Issue 5, pp. 1167 - 1168
Journal Article
Journal of Urology, The, ISSN 0022-5347, 2015, Volume 194, Issue 6, pp. 1537 - 1547
Purpose The availability of newly approved treatment options for metastatic castration resistant prostate cancer is not matched with conclusive data on optimal...
Urology | neoplasm metastasis | androgen antagonists | drug therapy | castration | prostatic neoplasms | MANAGEMENT | DOCETAXEL | PROGNOSTIC MODEL | PREDNISONE | CABAZITAXEL | MEN | UROLOGY & NEPHROLOGY | ABIRATERONE ACETATE | INCREASED SURVIVAL | CLINICAL ACTIVITY | ENZALUTAMIDE | Phenylthiohydantoin - adverse effects | Phenylthiohydantoin - therapeutic use | Humans | Male | Antineoplastic Agents - therapeutic use | Prostatic Neoplasms, Castration-Resistant - pathology | Taxoids - therapeutic use | Neoplasm Metastasis - drug therapy | Antineoplastic Agents - adverse effects | Prostatic Neoplasms, Castration-Resistant - therapy | Taxoids - adverse effects | Radioisotopes - therapeutic use | Androstenes - adverse effects | Radioisotopes - adverse effects | Docetaxel | Tissue Extracts - adverse effects | Androstenes - therapeutic use | Survival Rate | Radium - adverse effects | Tissue Extracts - therapeutic use | Radium - therapeutic use | Disease Progression | Phenylthiohydantoin - analogs & derivatives | Orchiectomy | Taxoids - administration & dosage | Neoplasm Metastasis - pathology | Androgen Antagonists - therapeutic use | Prostatic Neoplasms, Castration-Resistant - mortality | Androgen Antagonists - adverse effects | Neoplasm Staging | Medical colleges | Care and treatment | Metastasis | Prostate cancer
Urology | neoplasm metastasis | androgen antagonists | drug therapy | castration | prostatic neoplasms | MANAGEMENT | DOCETAXEL | PROGNOSTIC MODEL | PREDNISONE | CABAZITAXEL | MEN | UROLOGY & NEPHROLOGY | ABIRATERONE ACETATE | INCREASED SURVIVAL | CLINICAL ACTIVITY | ENZALUTAMIDE | Phenylthiohydantoin - adverse effects | Phenylthiohydantoin - therapeutic use | Humans | Male | Antineoplastic Agents - therapeutic use | Prostatic Neoplasms, Castration-Resistant - pathology | Taxoids - therapeutic use | Neoplasm Metastasis - drug therapy | Antineoplastic Agents - adverse effects | Prostatic Neoplasms, Castration-Resistant - therapy | Taxoids - adverse effects | Radioisotopes - therapeutic use | Androstenes - adverse effects | Radioisotopes - adverse effects | Docetaxel | Tissue Extracts - adverse effects | Androstenes - therapeutic use | Survival Rate | Radium - adverse effects | Tissue Extracts - therapeutic use | Radium - therapeutic use | Disease Progression | Phenylthiohydantoin - analogs & derivatives | Orchiectomy | Taxoids - administration & dosage | Neoplasm Metastasis - pathology | Androgen Antagonists - therapeutic use | Prostatic Neoplasms, Castration-Resistant - mortality | Androgen Antagonists - adverse effects | Neoplasm Staging | Medical colleges | Care and treatment | Metastasis | Prostate cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2012, Volume 367, Issue 13, pp. 1187 - 1197
In a study involving nearly 1200 men with metastatic prostate cancer who had progressive disease after chemotherapy, enzalutamide, a novel androgen-receptor...
INSTRUMENT | MEDICINE, GENERAL & INTERNAL | THERAPY | ANTIANDROGEN | FUNCTIONAL ASSESSMENT | ANDROGEN-RECEPTOR | CLINICAL-TRIALS | RESISTANCE | MECHANISMS | CARCINOMA | ABIRATERONE | Phenylthiohydantoin - adverse effects | Multivariate Analysis | Androgen Receptor Antagonists - therapeutic use | Double-Blind Method | Phenylthiohydantoin - therapeutic use | Prostatic Neoplasms - surgery | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Antineoplastic Agents - therapeutic use | Androgen Receptor Antagonists - adverse effects | Phenylthiohydantoin - analogs & derivatives | Prostatic Neoplasms - mortality | Orchiectomy | Seizures - chemically induced | Disease-Free Survival | Taxoids - therapeutic use | Neoplasm Metastasis - drug therapy | Signal Transduction - drug effects | Antineoplastic Agents - adverse effects | Aged | Prostatic Neoplasms - drug therapy | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Product/Service Evaluations | Drug therapy | Prostate cancer | Methods | Cancer | Prostate-specific antigen | Diarrhea | Clinical trials | Fatigue | Survival | Metastases | Testosterone | Signal transduction | Androgens | Chemotherapy | Pain | Castration | Men | Prostate | Seizures
INSTRUMENT | MEDICINE, GENERAL & INTERNAL | THERAPY | ANTIANDROGEN | FUNCTIONAL ASSESSMENT | ANDROGEN-RECEPTOR | CLINICAL-TRIALS | RESISTANCE | MECHANISMS | CARCINOMA | ABIRATERONE | Phenylthiohydantoin - adverse effects | Multivariate Analysis | Androgen Receptor Antagonists - therapeutic use | Double-Blind Method | Phenylthiohydantoin - therapeutic use | Prostatic Neoplasms - surgery | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Antineoplastic Agents - therapeutic use | Androgen Receptor Antagonists - adverse effects | Phenylthiohydantoin - analogs & derivatives | Prostatic Neoplasms - mortality | Orchiectomy | Seizures - chemically induced | Disease-Free Survival | Taxoids - therapeutic use | Neoplasm Metastasis - drug therapy | Signal Transduction - drug effects | Antineoplastic Agents - adverse effects | Aged | Prostatic Neoplasms - drug therapy | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Product/Service Evaluations | Drug therapy | Prostate cancer | Methods | Cancer | Prostate-specific antigen | Diarrhea | Clinical trials | Fatigue | Survival | Metastases | Testosterone | Signal transduction | Androgens | Chemotherapy | Pain | Castration | Men | Prostate | Seizures
Journal Article
Lancet Oncology, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 152 - 160
Summary Background Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in...
Hematology, Oncology and Palliative Medicine | MITOXANTRONE | CABAZITAXEL | ONCOLOGY | DOCETAXEL | ENZALUTAMIDE | Bone Neoplasms - mortality | Prognosis | Double-Blind Method | Follow-Up Studies | Humans | Androstenes - therapeutic use | Antineoplastic Combined Chemotherapy Protocols | Bone Neoplasms - secondary | Male | Survival Rate | Prostatic Neoplasms, Castration-Resistant - drug therapy | Disease Progression | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - therapeutic use | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Bone Neoplasms - drug therapy | Neoplasm Staging | Prednisone - therapeutic use | Chemotherapy | Corticosteroids | Analysis | Prednisone | Metastasis | Prostate cancer | Cancer
Hematology, Oncology and Palliative Medicine | MITOXANTRONE | CABAZITAXEL | ONCOLOGY | DOCETAXEL | ENZALUTAMIDE | Bone Neoplasms - mortality | Prognosis | Double-Blind Method | Follow-Up Studies | Humans | Androstenes - therapeutic use | Antineoplastic Combined Chemotherapy Protocols | Bone Neoplasms - secondary | Male | Survival Rate | Prostatic Neoplasms, Castration-Resistant - drug therapy | Disease Progression | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - therapeutic use | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Bone Neoplasms - drug therapy | Neoplasm Staging | Prednisone - therapeutic use | Chemotherapy | Corticosteroids | Analysis | Prednisone | Metastasis | Prostate cancer | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2010, Volume 363, Issue 5, pp. 411 - 422
The authors report increased survival among patients with advanced hormone-refractory prostate cancer who were vaccinated against a tumor antigen....
SURVIVAL | MEDICINE, GENERAL & INTERNAL | MITOXANTRONE PLUS PREDNISONE | DENDRITIC CELLS | CLINICAL-TRIALS | PHASE-III | MEN | RANDOMIZED CONTROLLED-TRIAL | SURROGATE MARKER | LEUKEMIA | DOCETAXEL | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Prostatic Neoplasms - therapy | Cancer Vaccines - therapeutic use | Aged, 80 and over | Cell Culture Techniques | Intercellular Adhesion Molecule-1 - adverse effects | Prostatic Neoplasms - drug therapy | Intercellular Adhesion Molecule-1 - therapeutic use | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Tissue Extracts - adverse effects | Cancer Vaccines - adverse effects | Combined Modality Therapy | Tissue Extracts - therapeutic use | Disease Progression | Prostatic Neoplasms - mortality | Immunotherapy - adverse effects | Antigen-Presenting Cells | Androgen Antagonists - therapeutic use | Aged | Infusions, Intravenous | Clinical trials | Drug therapy | Prostate cancer | Men
SURVIVAL | MEDICINE, GENERAL & INTERNAL | MITOXANTRONE PLUS PREDNISONE | DENDRITIC CELLS | CLINICAL-TRIALS | PHASE-III | MEN | RANDOMIZED CONTROLLED-TRIAL | SURROGATE MARKER | LEUKEMIA | DOCETAXEL | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Prostatic Neoplasms - therapy | Cancer Vaccines - therapeutic use | Aged, 80 and over | Cell Culture Techniques | Intercellular Adhesion Molecule-1 - adverse effects | Prostatic Neoplasms - drug therapy | Intercellular Adhesion Molecule-1 - therapeutic use | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Tissue Extracts - adverse effects | Cancer Vaccines - adverse effects | Combined Modality Therapy | Tissue Extracts - therapeutic use | Disease Progression | Prostatic Neoplasms - mortality | Immunotherapy - adverse effects | Antigen-Presenting Cells | Androgen Antagonists - therapeutic use | Aged | Infusions, Intravenous | Clinical trials | Drug therapy | Prostate cancer | Men
Journal Article